Northern Trust Corp increased its holdings in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 11.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 518,673 shares of the biotechnology company’s stock after purchasing an additional 54,142 shares during the quarter. Northern Trust Corp owned 1.14% of bluebird bio worth $54,487,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BLUE. Bank of Montreal Can increased its position in shares of bluebird bio by 118.9% during the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 911 shares during the last quarter. Turner Investments LLC acquired a new position in bluebird bio in the 2nd quarter valued at about $184,000. SG Americas Securities LLC grew its position in bluebird bio by 17.9% in the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 295 shares in the last quarter. Affinity Investment Advisors LLC acquired a new position in bluebird bio in the 2nd quarter valued at about $246,000. Finally, Teacher Retirement System of Texas acquired a new position in bluebird bio in the 1st quarter valued at about $291,000.

Several brokerages have recently issued reports on BLUE. Jefferies Group LLC reiterated a “buy” rating on shares of bluebird bio in a research note on Thursday, July 6th. Cantor Fitzgerald set a $39.00 target price on bluebird bio and gave the stock a “sell” rating in a research note on Saturday, June 24th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $186.00 price objective on shares of bluebird bio in a research note on Friday. Leerink Swann reiterated an “outperform” rating and issued a $145.00 price objective (up previously from $120.00) on shares of bluebird bio in a research note on Friday. Finally, Sanford C. Bernstein started coverage on bluebird bio in a research note on Thursday, July 27th. They issued a “market perform” rating and a $109.00 price objective for the company. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the company. bluebird bio currently has a consensus rating of “Hold” and a consensus price target of $113.41.

Shares of bluebird bio, Inc. (NASDAQ BLUE) opened at 127.75 on Friday. bluebird bio, Inc. has a 12 month low of $37.05 and a 12 month high of $143.50. The stock has a 50 day moving average price of $121.47 and a 200 day moving average price of $100.75. The firm’s market cap is $5.82 billion.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). The firm had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. bluebird bio’s revenue for the quarter was up 977.4% on a year-over-year basis. During the same quarter last year, the company posted ($1.59) EPS. On average, equities research analysts expect that bluebird bio, Inc. will post ($6.85) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “bluebird bio, Inc. (BLUE) Position Increased by Northern Trust Corp” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/bluebird-bio-inc-blue-position-increased-by-northern-trust-corp/1614733.html.

In other bluebird bio news, Director John Maraganore sold 18,868 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $131.21, for a total value of $2,475,670.28. Following the transaction, the director now directly owns 24,711 shares of the company’s stock, valued at approximately $3,242,330.31. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider David Davidson sold 3,000 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $92.37, for a total transaction of $277,110.00. Following the completion of the transaction, the insider now directly owns 18,977 shares in the company, valued at $1,752,905.49. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 129,379 shares of company stock valued at $15,651,533. Company insiders own 3.90% of the company’s stock.

bluebird bio Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.